Bristol Myers on Friday said the Phase 3 study of Reblozyl with concomitant janus-kinase-inhibitor therapy didn't meet its primary endpoint of red-blood-cell transfusion independence in adults with ...

Bristol Myers Squibb (BMY) stock slips as its anemia drug Reblozyl misses primary goal in a Phase 3 trial for myelofibrosis, ...

Bristol Myers' Reblozyl missed its primary goal in a Phase 3 anemia trial but showed positive secondary outcomes in ...

Despite a phase 3 flop, Bristol Myers Squibb—encouraged by “clinically meaningful results” and bruised by three other recent ...

US pharma major Bristol Myers Squibb’s shares remained steady, despite the company reporting disappointing results from its ...

Despite the failure, BMS remains “encouraged” by Reblozyl’s clinical activity in myelofibrosis-associated anemia and will approach regulators to discuss potential submissions for this indication, for ...

The anemia treatment missed its main goal in a myelofibrosis study. Meanwhile, Blenrep's return to the U.S. market may have ...

Bristol Myers' (BMY) sBLA seeking label expansion of Reblozyl for the treatment of anemia in adults with non-transfusion dependent (NTD) beta thalassemia gets priority review by the FDA.

Despite not meeting the endpoint, subjects have experienced a meaningful improvement in RBC transfusion independence.

Bristol-Myers Squibb Company (NYSE:BMY) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. The company has ...

Topline data were announced from a phase 3 trial evaluating luspatercept-aamt plus Janus kinase 2 inhibitor (JAKi) therapy in adults with myelofibrosis-associated anemia receiving red blood cell (RBC) ...

Bristol Myers’ (BMY) is striving hard for the label expansion of its key drugs. The company’s growth portfolio comprises ...